Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lurasidone 20 mg | Experimental |
| |
| Lurasidone 60 mg | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lurasidone 20 mg | Drug | Lurasidone 20 mg once daily orally in the evening |
|
| Measure | Description | Time Frame |
|---|---|---|
| MADRS | Mean change from baseline in MADRS total score after 6 weeks of treatment | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| CGI-S | Global severity assessed by the CGI-S score (depression) | 6 weeks |
Not provided
Inclusion Criteria:
Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.
Subject is 18 to 75 years of age, inclusive. Subject has MDD (diagnosed by DSM-IV-TR, and confirmed by the Structured Clinical Interview for DSM-IV Disorders - Clinical Trial version [SCID-CT]).
Subject is currently experiencing a major depressive episode (diagnosed by DSM-IV-TR; at least 2 weeks in duration) AND two or three of the following manic symptoms occurring on most days over at least the last 2 weeks (confirmed by the SCID-CT modified for Study D1050305):
Exclusion Criteria:
Subject has Axis I or Axis II diagnosis other than MDD that has been the primary focus of treatment within the 3 months prior to screening Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the C-SSRS (at time of evaluation) at screening or baseline visit.
Subject has attempted suicide within the past 3 months. Subject has a lifetime history of any bipolar I manic or mixed manic episode. Subject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director, MD | Sumitomo Pharma America, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Birmingham Research Group | Birmingham | Alabama | 35216 | United States | ||
| Sun Valley Behavioral Medical |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33065813 | Derived | Goldberg JF, Siu C, Mao Y, Tsai J, Pikalov A, Calabrese JR, Loebel A. Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model. J Affect Disord. 2020 Dec 1;277:1045-1054. doi: 10.1016/j.jad.2020.08.048. Epub 2020 Aug 26. | |
| 26552942 | Derived | Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, Pikalov A, Loebel A. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2016 Apr 1;173(4):400-7. doi: 10.1176/appi.ajp.2015.15060770. Epub 2015 Nov 10. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Lurasidone 60 mg | Drug | Lurasidone 60 mg once daily orally in the evening |
|
|
| Placebo | Drug | Placebo once daily orally in the evening |
|
| Imperial |
| California |
| 92251 |
| United States |
| Synergy Clinical Research Center | National City | California | 91950 | United States |
| Excell Research | Oceanside | California | 92056 | United States |
| Pacific Clinical Research Medical Group | Orange | California | 92868 | United States |
| SMRI | Sherman Oaks | California | 91403 | United States |
| Sarkis Clinical Trials | Gainesville | Florida | 32607 | United States |
| Florida Research Center | Maitland | Florida | 32751 | United States |
| University of Miami, Miller School | Miami | Florida | 33136 | United States |
| Miami Research | Miami | Florida | 33143 | United States |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30308 | United States |
| Comprehensive NeuroScience Inc. | Atlanta | Georgia | 30328 | United States |
| Hawaii Clinical Research Center | Honolulu | Hawaii | 86813 | United States |
| Psychiatric Medicine Associates | Skokie | Illinois | 60076 | United States |
| Goldpoint Clinical Research | Indianapolis | Indiana | 46260 | United States |
| CRI Worldwide | Willingboro | New Jersey | 08054 | United States |
| Medical & Behavioral Health Research | New York | New York | 10023 | United States |
| Montefiore Medical Center; Anxiety & Depression Clinic; Dept. of Psychiatry | The Bronx | New York | 10467 | United States |
| New Hope Clinical Research | Hickory | North Carolina | 28601 | United States |
| Sooner Clinical Research | Oklahoma City | Oklahoma | 73112 | United States |
| Lehigh Center for Clinical Research | Allentown | Pennsylvania | 18104 | United States |
| Suburban Research Associates | Media | Pennsylvania | 19063 | United States |
| Harry Croft and Associates | San Antonio | Texas | 78229 | United States |
| University of Texas Health Science Center | San Antonio | Texas | 78229 | United States |
| Grayline Clinical Drug Trials | Wichita Falls | Texas | 76309 | United States |
| Department of Psychiatry, University of Utah Health Sciences Center | Salt Lake City | Utah | 84132 | United States |
| Northwest Clinical Research Center | Bellevue | Washington | 98007 | United States |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003863 | Depression |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069056 | Lurasidone Hydrochloride |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D054833 | Isoindoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided